Biotechnology Companies in Spain

High density and high resolution graphene intelligent neural systems for central and peripheral Neuroelectronic applications

We took telemedicine to a whole new level. Invented the first Precision Medicine platform. And didn't survive the Covid-19 crisis. Thank you. We'll miss you.

Neuroelectrics® is a digital brain health company that innovates at the intersection of neuroscience, physics, machine learning, and hardware. We have developed wireless EEG and tDCS/tACS/tRNS stimulation devices with up to 32 channels, amongst other products encompassing software and research services, with the purpose of monitoring and enhancing brain health.

A new medicine R&D engine (R&D pharma company) operated by an experienced team dedicated to the discovery and development of new medicines to treat patient suffering from severe diseases of the central nervous system. Accure Therapeutics focuses on neurons that suffer a dysfunction, and on the glial environment that supports them, in an attempt to impede their degeneration and death. We work to find new medicines that correct the pathological changes that are responsible for the disease, and that produce beneficial outcomes (i.e. Disease Modifying Therapies). We specialize in developing drugs that promote neuroprotection and neurorepair by integrating the latest advances in neurobiology with state-of-the-art clinical research. We have currently built up a drug candidate portfolio that focuses on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy.

AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.

aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept.

ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. ARTHEx has developed its proprietary technology, the ENTRY ™ platform, that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevant tissues in pharmacological quantities, in order to treat diseases in which microRNAs play a key role. The first investigational product from this platform is ATX-01, an antimiR in preclinical development for Myotonic Dystrophy Type 1 (DM1). DM1 is an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000) with no cure, nor approved treatment to date. ATX-01 is a first-in-class disease-modifying therapy that addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis. To learn more about Arthex Biotech, please visit us at www.arthexbiotech.com

CUBIQ FOODS | Transforming the future of nutrition We are on a mission to improve nutrition around the world. Everything we do is focused on radically improving sustainability, health and nutritional profile, with affordability in mind. We also prioritize the consumers’ organoleptic experience across as many products as possible. As an international food tech company, we combine our scientific knowledge and expertise with the latest advances to provide an innovative range of alternative fats. We lead in three distinct processes; a novel oil/water emulsion, Omega-3 micro-encapsulation techniques, and the first cell-culture platform for specialty fats (cell-based Omega-3). Our solutions to the food industry support the development of high-quality processed food. We achieve this by reducing animal and saturated fats while retaining flavor and texture. We deliver health and nutritional benefits and reduce the calorie content. Our innovative platforms can tune for hardness, texture, and flavor as well as fat content in bespoke product applications. We produce and sell at scale and license production to select producers worldwide. Let’s change food from the inside!

Feedect is a leading company in the sustainable food industry, committed to producing high-quality proteins from insects. By leveraging the exceptional nutritional value of insects and their low environmental footprint, Feedect is transforming the way we feed the world. Our innovative production processes allow us to create a wide range of insect-based products, including protein powders, which are rich in essential amino acids, vitamins, minerals and natural prebiotic compounds. At Feedect, we believe that sustainable food production is key to preserving our planet and securing a better future for generations to come. We are proud to be at the forefront of this movement, providing healthy and sustainable food options that contribute to a more responsible and ethical food system. Join us in our mission to create a more sustainable food future. Follow our page to stay up to date on our latest developments, products and initiatives.

GoodGut is a biotechnology company focused on researching and developing analysis systems and therapeutic products to improve the diagnosis and treatment of digestive diseases based on intestinal microbiota. We aim to provide technological tools that will help to obtain a faster, more reliable and lower cost medical diagnosis than existing methods, alongside therapies to improve the quality of life of patients with compromised digestive health. The company was created in 2014 as a spin-off of the University of Girona (UdG) and the Institute of Biomedical Research of Girona Dr. Josep Trueta (IdIBGi). Our facilities can be found in the Scientific and Technologic Park of the UdG, an innovation hub housing over 140 companies, research groups and institutions.

Methinks vision is to provide universal and timely diagnosis for life-saving treatments worldwide. Our first focus is on stroke, the second cause of death and a major cause of disability in the world. Our product is an artificial intelligence medical imaging software capable of performing stroke triage and unlock stroke treatments potential from non-contrast CTs. Methinks is a VC backed digital health start-up that recently won the prestigious EIC Accelerator of the European Commission and has obtained two gold medals in the RSNA Kaggle competitions. The recent funding of the company will allow us to grow rapidly and we are looking for exceptional and passionate individuals to help us face these challenges and build together a unique company.

Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million

Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks. The company was founded in 2000 and has offices in Spain and the United States.

We are experts in developing novel sub-unit vaccines Our initial focus is on animal health. We aim to capitalize on the first approval of a CrisBio® - based vaccine dossier (expected in 2020) to expand into human health and thereby fully exploit the platform’s potential. CrisBio® also has applications in the Diagnostics sector, where it is already being exploited by a commercial partner. Our current portfolio comprises 6 vaccines across livestock species. Proof of concepts have been generated in > 20 additional vaccine antigens Value through collaborations Our go to market strategy is inherently linked to collaborations. We offer: • Development of tailor-made baculovirus vectors optimized for industrial production. • Proof-of-concept studies to validate the production of recombinant proteins in CrisBio®. • Supply of recombinant proteins produced in CrisBio® through license agreements. • Development of proprietary portfolios. Algenex is led by an internationally experienced management team, that is supported by a well-balanced Strategic Advisory Board that combines industry and investment experience.

THYTECH is a spin-off of the Gregorio Marañón Health Research Institute (IISGM) that was created with the aim of transferring to the patient our patented technology for the treatment of diseases related to immune disorders. The company arises from the work carried out by the researchers of the Immunoregulation Laboratory, and our main asset is a cellular therapy with thyTreg cells that is pioneering in the world that can establish a new paradigm in the prevention of transplant rejection and in the treatment of autoimmune diseases and clinical worsening of COVID patients.

Libre Foods is the first biotech and climate-driven company to develop whole-cut meats such as "chicken" breast and steak from the power of fungi through biomass fermentation. 🍄 Libre Bacon, their first product to hit the market in 2022, is made from all-natural ingredients, and its core ingredient is mushrooms. Libre Bacon has been greatly received by Madrid, Barcelona, and Valencia restaurants and will soon be getting into people's homes. Libre Bacon is only the first step in Libre's journey to creating a more just, sustainable, and free future for all. A future where you can enjoy your Sunday breakfast, late-night burger, or midweek lunch while caring for yourself, others, the animals, and the planet. All at once. The Libre team believes in fungi to minimize the environmental impact of food production and the power of biomass fermentation to push food technology's boundaries—the mixture of these two variables has already shown significant progress in creating delicious and environmentally friendly meat alternatives. Reach out to find out how significant... 😎

Bitbrain was founded in 2010 as a spin-off company of a research team from the University of Zaragoza, pioneer in approaching brain-computer interface applications outside laboratory investigation settings. Its DNA holds all knowledge in neurotechnology, biomedical engineering, artificial intelligence and data science accumulated at the university since 1998. Nowadays, the R+D+I bet is still strong, which has converted the company in a world reference for B2B neurotechnology solutions.

We specialise in producing sustainable plant extracts with proven health benefits. Our expert team conducts through research and development to deliver high-performance, top-quality solutions across diverse industries. Our products are upheld to a level of quality that exceeds the most rigorous standards in the industry. Plant sources are certified additionally through HABOID, a proprietary analytical method, which guarantees the purest botanical products possible. Sustainability is integral to our business model. Natac systematically analyses agricultural processes throughout the botanical industry to discover points in production that have the potential for intervention and investment. Our goal is to use the whole plant in order to access its full potential and thereby reduce the environmental impact of production. Internationally present with established markets around the world, Natac maintains the strategic location of our manufacturing, R&D and Innovation Unit, and Quality Department in Spain, which secures European standards.

Bio-Cord pertenece al mayor grupo de laboratorios clínicos más avanzado de Europa. El grupo cuenta con 1.000 empleados, realizando al día hasta 20.000 análisis clínicos y con 75.000 unidades de cordón conservadas. 18 años de trayectoria conservando y procesando células madre bajo la mayor rigurosidad y las máximas acreditaciones de calidad del sector. En Bio-Cord invertimos en investigación y desarrollo de nuevas tecnologías y por ello ofrecemos los mejores y más completos servicios; con nosotros las células de tu bebé están en las mejores manos. Bio-Cord es el proveedor oficial seleccionado por las principales compañías de salud en España.

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. Gate2Brain pursues its goals using a radically innovative peptide-based patented technology platform. G2B-002, Gate2Brain flagship product and proof of concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare paediatric cancers.

Point-of-Care (POC) technologies, designed to provide rapid clinical diagnosis at, or near the site of patient care, has the potential to sense changes in well-known biomarkers used already to monitor patients with chronic cardiac and respiratory diseases. However, they need to be measured in blood, which limit their use only in medical institutions. Our non-invasive products based on wearable formats will empower the patients and their families to measure relevant biomarkers anytime and anywhere, allowing them to detect and monitor early stages of possible clinical deterioration, which could prelude in earlier (self-)management strategies, resulting in shorter hospital stays and prevention of unnecessary treatments. Our social impact will be a priority. Our challenge is addressed to patients of all ages, from neonates with congenital heart disease and bronchiolitis’, to the elderly with chronic heart failure due to myocardial infarction or chronic lung diseases and asthma. Our product offers continuous, non-invasive monitoring that have a positive health impact to the health deterioration. We will support active aging and improve the self-management of health.

DD BioLab es un proveedor global de consumibles, equipos científicos, servicios y soluciones integradas para el laboratorio, centrado en el Mercado Ibérico. Compañía fundada en Febrero de 2014 y perteneciente al Grupo Dutscher, líder europeo en su mercado específico. Con una línea de productos altamente diversificada y dirigida tanto a los principales centros de investigación, desarrollo e innovación públicos y privados, que operan en los sectores de Investigación, Académico, Ciencias de la Vida, Químico, Farmacéutico, Biotecnológico, Industrial y de la Salud y la Seguridad; como a los laboratorios en general de cualquier sector industrial, con claro enfoque para el mercado Ibérico.

OPERON is a private Spanish company founded as a family business in 1973 engaged during the last 50 years in R&D innovation and manufacturing of In Vitro Diagnostics IVD. Active in the clinical diagnostics, in the veterinary field and in the food industry checking frauds in milk. The company is ISO 9001:2000 and ISO 13.485:2008 certified complying with cGMP . OPERON employs above 80 highly skilled and experienced people, 20 of them involved in R&D work. OPERON controls the whole added value chain of a new IVD test. Starting with the design of the raw materials, producing the kits and selling the IVD test to the end users through distributors or through its partners channels. OPERON is active in 4 different areas: 1. Lateral Flow Tests, more than 20 years experience. Working on a 3rd quantitative generation using fluorescent particles and a portable Point Of Care POC reading instrument. 2. Molecular Biology tests, based on different technologies: hybridization on strip (Opegen products), and Real Time PCR. All these products are based on the capture with specific probes of DNA fragments amplified by a conventional PCR. 3. Raw Materials: Develops Monoclonal Antibodies and Recombinant Antigens and produces them also in bioreactors and fermentors at industrial scale. 4. All our know how is available as a service. Development of new Monoclonal Antibodies and Recombinant Antigens, large scale production, purification. The development of innovative IVD tests is our most challenging task. Exporting more than 90% of its turnover mainly to Europe, US, Japan and 50 more countries. OPERON currently sells its brand name products using a network of distributors around the world, but our largest activity is to manufacture OEM kits or to supply in bulk to leading companies in the IVD sector.

Somos una empresa pionera y líder en la fabricación de diluyentes, materiales y automatización de procesos para la Inseminación Artificial Animal. Germinado en el Instituto de Investigación, INIA, nos constituimos como empresa en febrero de 1986 y desde el inicio con vocación global, hoy exportamos a más de 55 países. Nuestros diluyentes para semen porcino son reconocidos a nivel mundial por su alta calidad y alta protección espermática. Nos esforzamos en la formación y divulgación del progreso en las técnicas de IA. KUBUS S.A. is a pioneer Spanish biotechnology company and leader in the manufacture of extenders, consumables, equipment and supplements for Animal Artificial Insemination. The company was established in February 1986 and since its foundation has exported its products to more than 55 countries. Our extenders are recognized worldwide for its high quality. Since its foundation KUBUS has focused its efforts on improving and disseminating the advancement in assisted reproduction and hundreds of professionals have trained with us and spread the technique in all parts of the world. We are proud of the history of this company and we invite all those people who want to contribute their knowledge in the improvement of reproduction techniques to get in touch with us.

EpiXlife is a biotechnology company based in Valencia, Spain, specializing in innovative wellness solutions for healthcare professionals.

We empower professionals across Argentina, Brazil, Colombia, Mexico, Spain, and Uruguay with cutting-edge technologies and personalized training.

EpiXlife distinguishes itself through its integrated approach, combining advanced bioprobes, comprehensive training programs, and targeted marketing strategies, all supported by ongoing expert support. We are dedicated to transforming the wellness industry and helping professionals maximize their impact on patient lives.

Our mission is to provide professionals with the tools and knowledge they need to thrive in a rapidly evolving landscape, fostering a future where wellness is accessible and effective for all.

MedLumics is a medical device company with the goal of taking the latest technological and scientific developments in biophotonics and turning them into innovative and quality products to improve the quality of life. Our work is focused on one of the most successful light-based diagnostic techniques, Optical Coherence Tomography, which is currently seeing rapid expansion and growth. Our disruptive technological advantages allow us to offer unique medical solutions and to develop the clinical applications of this imaging modality. MedLumics, Enlightening Healthcare

ONA Therapeutics is a biotech company, spin-off of ICREA and IRB, specializes in unravelling novel biology to design biopharmaceuticals attacking advanced cancer.

LentiStem is R&D medical biotechnology company which develops platforms for improving safety and efficacy of advanced therapies and CAR-T cells.

My ADN Lab forma parte de la empresa Neodiagnostica. La exigencia y metodicidad de Neodiagnostica S.L. ha supuesto el máximo nivel de reconocimiento estatal. Neodiagnostica SL es una empresa de biotecnología con más de 10 años de trayectoria, que forma parte de un gran grupo. Formada por un equipo de biólogos, biotecnólogos, bioquímicos con una amplia experiencia en análisis de ADN. Nuestras técnicas y resultados están acreditados bajo la normativa de calidad ISO 17025 certificada por ENAC. Nuestro protocolo judicial permite que nuestros informes sean aceptados en cualquier órgano judicial del estado.

Nuestro propósito es ofrecer las mejores pruebas diagnósticas a los médicos y pacientes que las necesiten en cualquier parte del mundo.

SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.

At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery.